Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Viking Therapeutics Inc.

Developing “undervalued” assets for metabolic, endocrine disorders

This article was originally published in Start Up

Executive Summary

Viking Therapeutics Inc. has clinical-stage compounds for disorders amplifying as the world's population ages. The start-up’s first drug candidate is a potential treatment for people recovering from hip fracture; the second shows promise for fatty liver disorders that are spreading as the western diet does.

Advertisement

Related Content

Viking Flexes Its Muscles Ahead Of Partnering Talks

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register